3,3'-二吲哚甲烷（DIM）抑制表达 EGFR 突变体的耐药性人类癌细胞的生长和侵袭。
3,3'-Diindolylmethane (DIM) inhibits the growth and invasion of drug-resistant human cancer cells expressing EGFR mutants.
机构信息
Lombardi Comprehensive Cancer Center, Department of Oncology, Georgetown University Medical Center, Washington, DC 20057, United States.
出版信息
Cancer Lett. 2010 Sep 1;295(1):59-68. doi: 10.1016/j.canlet.2010.02.014. Epub 2010 Mar 17.
Abstract
Epidermal Growth Factor Receptor (EGFR) mutants are associated with resistance to chemotherapy, radiation, and targeted therapies. Here we found that the phytochemical 3,3'-Diindolylmethane (DIM) can inhibit the growth and also the invasion of breast cancer, glioma, and non-small cell lung cancer cells regardless of which EGFR mutant is expressed and the drug-resistant phenotype. DIM reduced an array of growth factor signaling pathways and altered cell cycle regulators and apoptotic proteins favoring cell cycle arrest and apoptosis. Therefore, DIM may be used in treatment regimens to inhibit cancer cell growth and invasion, and potentially overcome EGFR mutant-associated drug resistance.
摘要
表皮生长因子受体（EGFR）突变与化疗、放疗和靶向治疗的耐药性有关。在这里，我们发现植物化学物质 3,3'-二吲哚甲烷（DIM）可以抑制乳腺癌、神经胶质瘤和非小细胞肺癌细胞的生长和侵袭，而不管表达哪种 EGFR 突变和耐药表型。DIM 减少了一系列生长因子信号通路，并改变了细胞周期调节剂和凋亡蛋白，有利于细胞周期停滞和凋亡。因此，DIM 可用于治疗方案，以抑制癌细胞生长和侵袭，并可能克服 EGFR 突变相关的耐药性。
相似文献
1
3,3'-Diindolylmethane (DIM) inhibits the growth and invasion of drug-resistant human cancer cells expressing EGFR mutants.3,3'-二吲哚甲烷（DIM）抑制表达 EGFR 突变体的耐药性人类癌细胞的生长和侵袭。
Cancer Lett. 2010 Sep 1;295(1):59-68. doi: 10.1016/j.canlet.2010.02.014. Epub 2010 Mar 17.
2
244-MPT overcomes gefitinib resistance in non-small cell lung cancer cells.244-MPT克服非小细胞肺癌细胞中的吉非替尼耐药性。
Oncotarget. 2015 Dec 29;6(42):44274-88. doi: 10.18632/oncotarget.6236.
3
The HDAC inhibitor, MPT0E028, enhances erlotinib-induced cell death in EGFR-TKI-resistant NSCLC cells.组蛋白去乙酰化酶抑制剂 MPT0E028 增强 EGFR-TKI 耐药 NSCLC 细胞中厄洛替尼诱导的细胞死亡。
Cell Death Dis. 2013 Sep 19;4(9):e810. doi: 10.1038/cddis.2013.330.
4
Blocking epidermal growth factor receptor activation by 3,3'-diindolylmethane suppresses ovarian tumor growth in vitro and in vivo.3,3'-二吲哚甲烷通过阻断表皮生长因子受体的激活来抑制卵巢肿瘤在体外和体内的生长。
J Pharmacol Exp Ther. 2012 Apr;341(1):24-32. doi: 10.1124/jpet.111.188706. Epub 2011 Dec 28.
5
PLCγ1‑dependent invasion and migration of cells expressing NSCLC‑associated EGFR mutants.表达 NSCLC 相关 EGFR 突变的细胞中 PLCγ1 依赖性侵袭和迁移。
Int J Oncol. 2020 Oct;57(4):989-1000. doi: 10.3892/ijo.2020.5112. Epub 2020 Aug 19.
6
Met gene amplification and protein hyperactivation is a mechanism of resistance to both first and third generation EGFR inhibitors in lung cancer treatment.基因扩增和蛋白过度激活是肺癌治疗中对第一代和第三代 EGFR 抑制剂产生耐药的机制。
Cancer Lett. 2016 Oct 1;380(2):494-504. doi: 10.1016/j.canlet.2016.07.021. Epub 2016 Jul 19.
7
Lymecycline reverses acquired EGFR-TKI resistance in non-small-cell lung cancer by targeting GRB2.林可霉素通过靶向 GRB2 逆转非小细胞肺癌获得性 EGFR-TKI 耐药性。
Pharmacol Res. 2020 Sep;159:105007. doi: 10.1016/j.phrs.2020.105007. Epub 2020 Jun 17.
8
Ferumoxytol and CpG oligodeoxynucleotide 2395 synergistically enhance antitumor activity of macrophages against NSCLC with EGFR mutation.铁氧体纳米药物和 CpG 寡脱氧核苷酸 2395 协同增强 EGFR 突变型 NSCLC 中巨噬细胞的抗肿瘤活性。
Int J Nanomedicine. 2019 Jun 24;14:4503-4515. doi: 10.2147/IJN.S193583. eCollection 2019.
9
Amphiregulin triggered epidermal growth factor receptor activation confers in vivo crizotinib-resistance of EML4-ALK lung cancer and circumvention by epidermal growth factor receptor inhibitors.双调蛋白触发的表皮生长因子受体激活赋予EML4-ALK肺癌体内克唑替尼耐药性以及表皮生长因子受体抑制剂对其的规避。
Cancer Sci. 2017 Jan;108(1):53-60. doi: 10.1111/cas.13111. Epub 2016 Dec 30.
10
Apoptosis-inducing effect of erlotinib is potentiated by 3,3'-diindolylmethane in vitro and in vivo using an orthotopic model of pancreatic cancer.在体外和使用胰腺癌原位模型的体内实验中，3,3'-二吲哚甲烷可增强厄洛替尼的诱导凋亡作用。
Mol Cancer Ther. 2008 Jun;7(6):1708-19. doi: 10.1158/1535-7163.MCT-08-0354.
引用本文的文献
1
Combination Therapy Using Phytochemicals and PARP Inhibitors in Hybrid Nanocarriers: An Optimistic Approach for the Management of Colon Cancer.混合纳米载体中使用植物化学物质和PARP抑制剂的联合疗法：结肠癌治疗的一种乐观方法
Int J Mol Sci. 2025 Jul 30;26(15):7350. doi: 10.3390/ijms26157350.
2
Overcoming the Challenges of Phytochemicals in Triple Negative Breast Cancer Therapy: The Path Forward.克服三阴性乳腺癌治疗中植物化学物质的挑战：前进之路。
Plants (Basel). 2023 Jun 16;12(12):2350. doi: 10.3390/plants12122350.
3
Investigations on Anticancer and Antimalarial Activities of Indole-Sulfonamide Derivatives and Studies.吲哚 - 磺酰胺衍生物的抗癌和抗疟活性研究及相关研究
ACS Omega. 2021 Nov 18;6(47):31854-31868. doi: 10.1021/acsomega.1c04552. eCollection 2021 Nov 30.
4
Recent progress in natural dietary non-phenolic bioactives on cancers metastasis.天然饮食非酚类生物活性物质在癌症转移方面的最新进展。
J Food Drug Anal. 2018 Jul;26(3):940-964. doi: 10.1016/j.jfda.2018.05.003. Epub 2018 Jun 1.
5
Novel Aryl Hydrocarbon Receptor Agonist Suppresses Migration and Invasion of Breast Cancer Cells.新型芳烃受体激动剂抑制乳腺癌细胞的迁移和侵袭。
PLoS One. 2016 Dec 1;11(12):e0167650. doi: 10.1371/journal.pone.0167650. eCollection 2016.
6
Lipid-based oral delivery systems for skin deposition of a potential chemopreventive DIM derivative: characterization and evaluation.用于潜在化学预防 DIM 衍生物经皮沉积的基于脂质的口服递药系统：特性描述和评价。
Drug Deliv Transl Res. 2016 Oct;6(5):526-39. doi: 10.1007/s13346-016-0302-2.
7
Ultra-flexible nanocarriers for enhanced topical delivery of a highly lipophilic antioxidative molecule for skin cancer chemoprevention.用于增强高度亲脂性抗氧化分子局部递送以预防皮肤癌的超柔性纳米载体。
Colloids Surf B Biointerfaces. 2016 Jul 1;143:156-167. doi: 10.1016/j.colsurfb.2016.03.036. Epub 2016 Mar 15.
8
Aryl hydrocarbon receptor-microRNA-212/132 axis in human breast cancer suppresses metastasis by targeting SOX4.人乳腺癌中的芳烃受体-微小RNA-212/132轴通过靶向SOX4抑制转移。
Mol Cancer. 2015 Sep 17;14:172. doi: 10.1186/s12943-015-0443-9.
9
3'3-Diindolylmethane inhibits migration, invasion and metastasis of hepatocellular carcinoma by suppressing FAK signaling.3,3'-二吲哚甲烷通过抑制黏着斑激酶信号传导来抑制肝细胞癌的迁移、侵袭和转移。
Oncotarget. 2015 Sep 15;6(27):23776-92. doi: 10.18632/oncotarget.4196.
10
Microwave-assisted, one-pot reaction of 7-azaindoles and aldehydes: a facile route to novel di-7-azaindolylmethanes.7-氮杂吲哚与醛的微波辅助一锅法反应：合成新型二-7-氮杂吲哚甲烷的简便途径。
Tetrahedron Lett. 2014 Jan 1;55(1). doi: 10.1016/j.tetlet.2013.10.143.
本文引用的文献
1
EGFRvIII-induced estrogen-independence, tamoxifen-resistance phenotype correlates with PgR expression and modulation of apoptotic molecules in breast cancer.表皮生长因子受体Ⅷ（EGFRvIII）诱导的雌激素非依赖性、他莫昔芬耐药表型与乳腺癌中孕激素受体（PgR）表达及凋亡分子的调节相关。
Int J Cancer. 2009 Nov 1;125(9):2021-8. doi: 10.1002/ijc.24540.
2
EGFRvIII and c-Met pathway inhibitors synergize against PTEN-null/EGFRvIII+ glioblastoma xenografts.表皮生长因子受体III型变异体（EGFRvIII）和c-Met信号通路抑制剂联合使用对PTEN基因缺失/EGFRvIII阳性的胶质母细胞瘤异种移植瘤具有协同作用。
Mol Cancer Ther. 2009 Jul;8(7):1751-60. doi: 10.1158/1535-7163.MCT-09-0188. Epub 2009 Jul 7.
3
Targeting MET as a strategy to overcome crosstalk-related resistance to EGFR inhibitors.将MET作为克服与串扰相关的对EGFR抑制剂耐药性的一种策略。
Lancet Oncol. 2009 Jul;10(7):709-17. doi: 10.1016/S1470-2045(09)70137-8.
4
3,3'-diindolylmethane induction of p75NTR-dependent cell death via the p38 mitogen-activated protein kinase pathway in prostate cancer cells.3,3'-二吲哚甲烷通过p38丝裂原活化蛋白激酶途径诱导前列腺癌细胞中p75神经营养因子受体依赖性细胞死亡。
Cancer Prev Res (Phila). 2009 Jun;2(6):566-71. doi: 10.1158/1940-6207.CAPR-08-0202. Epub 2009 May 26.
5
3,3'-Diindolylmethane induces a G(1) arrest in human prostate cancer cells irrespective of androgen receptor and p53 status.3,3'-二吲哚甲烷可诱导人前列腺癌细胞出现G(1)期阻滞，且与雄激素受体和p53状态无关。
Biochem Pharmacol. 2009 Sep 1;78(5):469-76. doi: 10.1016/j.bcp.2009.05.008. Epub 2009 May 9.
6
Clinicopathologic and molecular features of epidermal growth factor receptor T790M mutation and c-MET amplification in tyrosine kinase inhibitor-resistant Chinese non-small cell lung cancer.表皮生长因子受体 T790M 突变和 c-MET 扩增在酪氨酸激酶抑制剂耐药的中国非小细胞肺癌中的临床病理和分子特征。
Pathol Oncol Res. 2009 Dec;15(4):651-8. doi: 10.1007/s12253-009-9167-8. Epub 2009 Apr 21.
7
The HER-2 receptor and breast cancer: ten years of targeted anti-HER-2 therapy and personalized medicine.HER-2受体与乳腺癌：十年靶向抗HER-2治疗及个性化医疗
Oncologist. 2009 Apr;14(4):320-68. doi: 10.1634/theoncologist.2008-0230. Epub 2009 Apr 3.
8
Novel therapeutic inhibitors of the c-Met signaling pathway in cancer.癌症中c-Met信号通路的新型治疗性抑制剂
Clin Cancer Res. 2009 Apr 1;15(7):2207-14. doi: 10.1158/1078-0432.CCR-08-1306. Epub 2009 Mar 24.
9
Enhancement of docetaxel anticancer activity by a novel diindolylmethane compound in human non-small cell lung cancer.一种新型二吲哚甲烷化合物增强多西他赛在人非小细胞肺癌中的抗癌活性
Clin Cancer Res. 2009 Jan 15;15(2):543-52. doi: 10.1158/1078-0432.CCR-08-1558.
10
Prognostic significance of c-Met expression in glioblastomas.c-Met表达在胶质母细胞瘤中的预后意义
Cancer. 2009 Jan 1;115(1):140-8. doi: 10.1002/cncr.23972.
Zotero 插件